GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Codiak BioSciences Inc (OTCPK:CDAKQ) » Definitions » Total Stockholders Equity

Codiak BioSciences (Codiak BioSciences) Total Stockholders Equity : $38.93 Mil (As of Sep. 2022)


View and export this data going back to 2020. Start your Free Trial

What is Codiak BioSciences Total Stockholders Equity?

Codiak BioSciences's Total Stockholders Equity for the quarter that ended in Sep. 2022 was $38.93 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Codiak BioSciences's Book Value per Share for the quarter that ended in Sep. 2022 was $1.06. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Codiak BioSciences's Debt-to-Equity for the quarter that ended in Sep. 2022 was 1.57.

Codiak BioSciences Total Stockholders Equity Historical Data

The historical data trend for Codiak BioSciences's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Codiak BioSciences Total Stockholders Equity Chart

Codiak BioSciences Annual Data
Trend Dec18 Dec19 Dec20 Dec21
Total Stockholders Equity
92.03 21.95 14.57 53.51

Codiak BioSciences Quarterly Data
Dec18 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 34.01 53.51 48.38 44.40 38.93

Codiak BioSciences  (OTCPK:CDAKQ) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Codiak BioSciences's Book Value per Share for the quarter that ended in Sep. 2022 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(38.929-0)/36.8296
=1.06

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Codiak BioSciences's Debt-to-Equity for the quarter that ended in Sep. 2022 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(3.011 + 58.266) / 38.929
=1.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Codiak BioSciences Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Codiak BioSciences's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Codiak BioSciences (Codiak BioSciences) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Codiak BioSciences Inc (OTCPK:CDAKQ) » Definitions » Total Stockholders Equity
Comparable Companies
TSOI SLS ORGS IFRX RAIN MDWD ODTC BSTG AKBA ENTX OCSE:NOVO B ASX:CSL REGN VRTX MRNA XKRX:207940 BNTX HKSE:02269 SGEN SZSE:300122
Traded in Other Exchanges
N/A
Address
35 Cambridge Park Drive, Suite 500, Cambridge, MA, USA, 02140
Website
https://www.codiakbio.com
Codiak BioSciences Inc is a development-stage biopharmaceutical company focused on the development of exosome-based therapeutics for the treatment of a wide spectrum of diseases with high unmet medical need. The company have utilized engEx Platform to generate a pipeline of engineered exosomes, aimed at treating a broad range of diseases, including oncology, neuro-oncology, neurology, neuromuscular disease, infectious disease and rare disease.
Executives
Yalonda Howze officer: See Remarks C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Sriram Sathyanarayanan officer: Chief Scientific Officer C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Nicole Barna officer: See Remarks C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Douglas E Williams director, officer: President & CEO C/O AMGEN INC, ONE AMGEN CENTER DR, THOUSAND OAKS CA 91320-1799
Linda Bain officer: Chief Financial Officer C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Konstantin Konstantinov officer: See Remarks C/O CODIAK BIOSCIENCES, INC., 500 TECHNOLOGY SQUARE, 9TH FLOOR, CAMBRIDGE MA 02139
Arch Venture Fund Viii Overage, L.p. 10 percent owner C/O ARCH VENTURE PARTNERS VIII, LLC, 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
David J Mauro officer: Chief Medical Officer 36 TERRELL DRIVE, WASHINGTON CROSS PA 18977
Arundathy N. Pandite director 1018 W 11TH ST., SUITE 100, AUSTIN TX 78703
Benny Sorensen officer: See Remarks C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Anne-virginie Eggimann director C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Jennifer J. Wheler officer: Chief Medical Officer C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Briggs Morrison director C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD, SUITE 110, WALTHAM MA 02451
Alaska Permanent Fund Corp 10 percent owner 801 WEST 10TH STREET, SUITE 302, JUNEAU AK 99801
Flagship Ventures Fund V, L.p. 10 percent owner ONE MEMORIAL DRIVE, 7TH FLOOR, CAMBRIDGE MA 02142